Randomized trial shows psilocybin improves cocaine abstinence rates in treated individuals — Evidence Review
Published in Jama Network Open, by researchers from University of Alabama at Birmingham
Researched by
— the AI search engine for science
Table of Contents
A new randomized controlled trial suggests that a single dose of psilocybin, combined with therapy, may help people with cocaine use disorder achieve higher abstinence rates compared to placebo. Related research generally supports the potential of psychedelic-assisted therapy for substance use disorders, though larger and more rigorous studies are needed to confirm these effects. The study from the University of Alabama at Birmingham adds important evidence to a growing field.
- Systematic reviews and clinical trials indicate that psilocybin and other classic psychedelics show promise in treating addictions—particularly for alcohol and tobacco—when combined with psychotherapy, but evidence for cocaine use disorder remains limited and calls for further research with larger and more diverse samples 1 3 4 5.
- The new study’s findings are consistent with previous research showing that psilocybin-assisted therapy can enhance psychological flexibility, reduce cravings, and promote abstinence across multiple substance use disorders, but rigorous placebo-controlled evidence for cocaine remains scarce 1 3 4.
- Despite encouraging results, related reviews emphasize the need for standardized protocols, long-term follow-up, and more diverse participant populations to ensure findings are broadly applicable and to address potential biases in psychedelic research 1 3 5.
Study Overview and Key Findings
Cocaine use disorder continues to present significant public health challenges, especially given the absence of FDA-approved pharmacological treatments for stimulant addictions. The urgency is underscored by rising global cocaine production and related mortality, as well as disproportionate impacts on marginalized communities. The trial led by Dr. Peter Hendricks at the University of Alabama at Birmingham is notable for enrolling a majority of Black participants—an underrepresented group in psychedelic research—and for its careful design to minimize expectation effects common in trials involving psychedelics.
This study provides early but important evidence on the potential for psilocybin-assisted therapy to support abstinence in individuals seeking to overcome cocaine addiction. The findings highlight the need for more diverse and representative research in this area.
| Property | Value |
|---|---|
| Study Year | 2023 |
| Organization | University of Alabama at Birmingham |
| Journal Name | Jama Network Open |
| Authors | Dr Peter Hendricks |
| Population | Participants with cocaine use disorder |
| Sample Size | n=36 |
| Methods | Randomized Controlled Trial (RCT) |
| Outcome | Cocaine abstinence rates |
| Results | Psilocybin group had higher abstinence than placebo group. |
Literature Review: Related Studies
To situate these findings in the broader scientific context, we searched the Consensus database, which includes over 200 million research papers. The following specific search queries were used to identify relevant studies:
- psilocybin cocaine addiction treatment
- magic mushrooms abstinence outcomes
- placebo effects psilocybin therapy
Below, we group the most relevant findings from the literature by key research questions:
| Topic | Key Findings |
|---|---|
| What is the evidence for psilocybin’s effectiveness in treating substance use disorders, including cocaine? | - Systematic reviews and clinical trials report that psilocybin-assisted therapy shows potential for reducing dependence and promoting abstinence in alcohol and tobacco use disorders, with early evidence suggesting possible benefits for cocaine use disorder, though rigorous research for cocaine is limited 1 3 4 5 6. - Most studies emphasize that combining psilocybin with psychotherapy amplifies positive outcomes 3 4 5 6. |
| What mechanisms may underlie psilocybin’s impact on addiction and mental health? | - Psychedelics, including psilocybin, are thought to enhance neuroplasticity and psychological flexibility, potentially enabling individuals to break maladaptive behavioral patterns associated with addiction 2 4 6. - Psilocybin induces altered states that can increase self-awareness, insight, and promote long-lasting behavioral change when paired with therapeutic support 1 4 6. |
| How robust and generalizable are the findings from current psilocybin studies? | - Many studies have small, homogenous samples—often with participants who are white and higher socioeconomic status—limiting generalizability; larger and more diverse trials are needed 1 3 5. - Placebo effects, participant expectations, and lack of standardized protocols are recurring methodological challenges in psychedelic research 1 3 5. |
| What is known about the safety and side effects of psilocybin-assisted therapy? | - Across studies, psilocybin was generally well-tolerated, with no serious adverse events reported in substance use disorder or mental health studies 5 7 8 9 11. - Some studies report transient increases in anxiety or other psychological discomfort during sessions, but these are typically mild and resolve without intervention 5 7 8 9. |
What is the evidence for psilocybin’s effectiveness in treating substance use disorders, including cocaine?
The majority of related studies focus on alcohol and tobacco use disorders, where psilocybin-assisted psychotherapy has produced significant reductions in use and increased abstinence rates 3 4 5 6. Evidence for cocaine use disorder is emerging but remains limited, with the new University of Alabama study representing one of the first randomized controlled trials in this area. Systematic reviews emphasize the need for larger, longer-term trials to confirm efficacy and determine whether findings from alcohol and tobacco studies extend to cocaine and other stimulants 1 3 5.
- Most positive results for psilocybin are reported in the context of alcohol and tobacco cessation, with less data for cocaine and other stimulants 3 4 5 6.
- Combining psilocybin with structured psychotherapy appears critical for achieving and maintaining abstinence 3 4 5.
- The new study helps address a gap in the literature by focusing on cocaine use disorder in a representative population 1 3.
- Overall, while early results are encouraging, more rigorous and larger-scale trials are needed for cocaine use disorder 1 3 5.
What mechanisms may underlie psilocybin’s impact on addiction and mental health?
Several studies propose that psilocybin’s therapeutic effects may stem from increased neuroplasticity and psychological flexibility, which could help individuals shift entrenched patterns of thought and behavior associated with addiction 2 4 6. The subjective effects—such as enhanced self-awareness, insight, and spiritual experiences—are also thought to contribute to lasting behavioral change, especially when integrated with psychotherapy 1 4 6.
- Psilocybin may help disrupt rigid, compulsive behaviors by amplifying the effects of psychotherapy 2 4.
- Subjective experiences during psilocybin sessions are often associated with increased insight, self-compassion, and motivation to change 1 4 6.
- Neurobiological changes following psilocybin administration may support recovery from addiction, though the exact mechanisms require further study 2 6.
- The ability to facilitate perspective shifts may be particularly relevant for substances like cocaine that have strong psychological withdrawal symptoms 6.
How robust and generalizable are the findings from current psilocybin studies?
While findings are promising, most studies to date have enrolled relatively small and homogenous samples—often disproportionately white and of higher socioeconomic status—which raises questions about how broadly results can be applied 1 3 5. The new University of Alabama trial is notable for including a majority of Black participants and for explicitly recruiting people seeking to quit cocaine, rather than psychedelic enthusiasts, which may improve the representativeness of its findings 1.
- Most existing research samples lack diversity, potentially limiting the broader applicability of results 1 3 5.
- Recruitment strategies and the “expectation effect” may bias outcomes in psychedelic studies 1 3.
- The need for standardized protocols and follow-up to better assess long-term outcomes is a recurring theme in the literature 1 3 5.
- The current study addresses some of these limitations by focusing on a representative clinical population and minimizing participant expectations 1.
What is known about the safety and side effects of psilocybin-assisted therapy?
Across reviewed studies, psilocybin administered in controlled, therapeutic settings has been well-tolerated, with few if any serious adverse events reported 5 7 8 9 11. Some participants may experience transient anxiety or discomfort during sessions, but these effects are typically mild and resolve without intervention. Safety monitoring and careful screening remain important, particularly for individuals with a history of severe mental illness 5 7 8 9 11.
- No serious adverse events were reported in randomized controlled trials or systematic reviews involving psilocybin for substance use or mental health disorders 5 7 8 9 11.
- Mild psychological side effects (such as anxiety or temporary distress) may occur during sessions 5 7 8.
- Longer-term follow-up suggests sustained benefits without significant safety concerns 7 9.
- Careful clinical protocols and screening are critical to minimize risks and ensure participant safety 5 7 8 9 11.
Future Research Questions
While the current study provides valuable new evidence for psilocybin’s potential in treating cocaine use disorder, several important questions remain. Key areas for future investigation include the long-term durability of effects, optimal integration with psychotherapy, mechanisms of action, safety in more diverse populations, and the generalizability of findings across different settings and substance use disorders.
| Research Question | Relevance |
|---|---|
| What are the long-term effects of psilocybin-assisted therapy for cocaine use disorder? | Understanding the durability of abstinence and psychological benefits is crucial for evaluating psilocybin’s true therapeutic impact, as most current studies have limited follow-up durations 1 3 5. |
| How do different psychotherapy approaches impact the effectiveness of psilocybin in treating substance use disorders? | The integration of psychotherapy appears essential for positive outcomes, but the optimal type, timing, and intensity of therapy alongside psilocybin remains unclear 3 4 5 6. |
| What are the neurobiological mechanisms underlying psilocybin’s effects on addiction and behavioral change? | Clarifying how psilocybin influences brain function and behavior may help optimize treatment protocols and identify individuals most likely to benefit 2 4 6. |
| How safe is psilocybin-assisted therapy for diverse populations, including those with comorbid mental health conditions? | Most studies exclude participants with significant psychiatric comorbidities, limiting the evidence base for real-world populations who often have complex health profiles 1 5. |
| Can the effects of psilocybin-assisted therapy for cocaine use disorder be replicated in larger multicenter clinical trials? | Replication in multi-site, larger-scale studies is necessary to confirm efficacy, improve generalizability, and assess implementation in different healthcare contexts 1 3 5. |